Form EFFECT - Notice of Effectiveness

S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

Form EFFECT - Notice of Effectiveness

Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Emergent Biosolutions Charts.

Emergent Biosolutions (NYSE:EBS)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Emergent Biosolutions Charts.

Emergent Biosolutions Inc News

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025
Tuesday 18 February 2025 (5 days ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 11 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans
Friday 7 February 2025 (2 weeks ago) • GlobeNewswire Inc.

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)
Thursday 16 January 2025 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 15 January 2025 (1 month ago) • Edgar (US Regulatory)

Form 8-K - Current report
Tuesday 14 January 2025 (1 month ago) • Edgar (US Regulatory)

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals
Tuesday 14 January 2025 (1 month ago) • GlobeNewswire Inc.

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola
Monday 13 January 2025 (1 month ago) • GlobeNewswire Inc.

Form 8-K - Current report
Wednesday 8 January 2025 (2 months ago) • Edgar (US Regulatory)

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
Wednesday 8 January 2025 (2 months ago) • GlobeNewswire Inc.

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)
Wednesday 8 January 2025 (2 months ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 17 December 2024 (2 months ago) • Edgar (US Regulatory)

More Emergent Biosolutions Inc News Articles

RespireRx Pharmaceuticals (CE)

Voip Pal Com (QB)

Rennova Health (CE)

Anavex Life Sciences

Intergrated Cannabis Sol... (PK)

Bioelectronics (PK)

North Bay Resources (PK)

Elite Pharmaceuticals (QB)

Digital Brand Media and ... (PK)

Northwest Biotherapeutics (QB)

Fannie Mae (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions